- Non-invasive spectroscopy
- Backed by Science, Powered by Data
- Provides an objective, non-visual assessment
- Non-Invasive, Sub-Millimeter Analysis
- 13% improvement in GPs' skin cancer detection1
1Data on file. DermaSensor use increased physicians’ cancer detection sensitivity from 81% to 94%, and this improvement was statistically significant (p = .0009). There was no statistically significant change in the GP’s specificity, or false positive rate, for benign lesions (p = .3558).
DermaSensor’s technology holds the promise of improving early detection of skin cancer by equipping primary care providers with a tool to better assess it.
David Leffell, M.D.
Chief, Section of Dermatologic Surgery
and Cutaneous Oncology, Yale School of Medicine
Scientific Advisory Board, DermaSensor
With improved performance and confidence in conducting skin cancer checks, you have the potential to significantly grow practice revenues. Speak to one of DermaSensor’s consultants to receive your fully customised FREE Practice Economics Report today.
DermaSensor looks beyond the visual to improve your decision-making and confidence.
According to the results of a study with 57 GPs, skin cancer detection increases by 13% (from 81% to 94% sensitivity) when using DermaSensor, with no significant decrease in specificity.